top of page

Connecting Patients to Treatments, Novel Therapies, and Clinical Trials

ODC Life Sciences serves as a partner for biopharma companies to access the large and diverse patient population of Latin America.


Our capabilities and expertise are focused on supporting global clients from the clinical development stage throughout the entire product lifecycle. 


We currently have 60 employees providing services across two verticals: 

Clinical Development
& CRO Services

& Early Access


Provide clinical trial treatment and access  for rare and high-complexity patients in Latin America.


Provide new clinical trial and treatment access opportunities to our patients and deliver our work with Excellence, Innovation, Commitment, Accountability, and Passion


Develop Pharma business in Latin America and advance our clients’ technologies using our local expertise.

ODC Background feixe luzes.jpg

Our Impact in Numbers


Rare Disease Patients Randomized



Phase I/II trials - 35%

Phase III/IV trials - 65%

2.6 months

Drug Dossier Approval

2.2 months

Protocol Dossier Approval

(Rare Disease Averages)

3.3 months

Drug Dossier Approval

3.4 months

Protocol Dossier Approval

(General Averages)

bottom of page